1-tert-Butylamino-4,4-dimethyl-pentan-3-one | 130539-88-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-tert-Butylamino-4,4-dimethyl-pentan-3-one
• 英文别名: 1-(Tert-butylamino)-4,4-dimethylpentan-3-one
• CAS: 130539-88-7
• 化学式: C₁₁H₂₃NO
• 分子量: 185.31
• InChiKey: OJSKFPVWTNVKBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (1-叔丁基乙烯氧基)三甲基硅烷 、 alkaline earth salt of/the/ methylsulfuric acid 以 二氯甲烷 为溶剂， 反应 2.0h， 以72%的产率得到1-tert-Butylamino-4,4-dimethyl-pentan-3-one
  参考文献：
  名称：

  由双-（烷氧基甲基）-烷基胺合成仲胺的新途径-氨基甲基的活化和相同官能团对产物的保护

  摘要：

  的治疗N，N- -双用各种酸性试剂，得到良好的产率的（烷氧基）烷基胺Ñ -alkoxymethyl- Ñ -alkylmethyleneiminium盐，其与三甲基甲硅烷烯醇醚反应，亲核芳族底物，通过多米诺形式保护的仲胺或叔胺反应; 甲硅烷基乙烯酮缩醛仅提供叔胺。

  DOI：

  10.1016/s0040-4039(00)97589-0

文献信息

• COMPOUNDS AND METHODS FOR MODULATING FRATAXIN EXPRESSION
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20170281643A1

  公开（公告）日：2017-10-05

  The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.

  本技术涉及用于调节基因表达的组合物和方法，其中包括一个目标寡核苷酸序列，例如包含3到10个核苷酸的特定寡核苷酸序列的重复。在特定方面，本技术涉及具有A-L-B公式的试剂，其中-L-是连接剂；A-是Brd4结合基团；-B是核酸结合基团，例如聚酰胺或互补寡核苷酸，可特异性结合目标寡核苷酸序列。
• Novel antibacterial agents
  申请人：Christensen G. Burton

  公开号：US20070134729A1

  公开（公告）日：2007-06-14

  This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.

  本发明涉及一种新型多结合化合物（药剂），其为抗菌剂。该发明的多结合化合物由2-10个配体通过连接剂或连接剂共价连接而成，其中每个单价（即未连接的）配体具有与细胞壁生物合成和代谢中的酶、合成细菌细胞壁和/或细菌细胞表面的前体有结合能力，从而干扰细胞壁的合成和/或代谢。特别地，本发明的多结合化合物由2-10个配体通过连接剂或连接剂共价连接而成，其中每个配体具有能够结合青霉素结合蛋白、横向肽酶酶、横向肽酶酶底物、β-内酰胺酶、青霉素酶、头孢菌素酶、横向转移酶酶或横向转移酶酶底物的配体结构域。优选地，配体选自β-内酰胺类或糖肽类抗菌剂。
• Nylon-3 co-polymers and synthetic lung surfactant compositions containing same
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US10736915B2

  公开（公告）日：2020-08-11

  Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of β-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B. Attachment of an N-terminal octadecanoyl unit to the nylon-3 copolymers affords further improvements by reducing the percent surface area compression to reach low minimum surface tension.

  非天然低聚物最近有望成为肺表面活性蛋白 B 和 C（SP-B 和 SP-C）的功能类似物，这两种螺旋状两亲性蛋白对正常呼吸至关重要。以前，SP-B 和 SP-C 的非天然模拟物的生成一直局限于分步、序列特异性合成，从而产生离散的低聚物，以显示特定的结构属性。本文介绍的另一种 SP-B 拟态方法是基于含有阳离子和亲油亚单位的序列随机共聚物。这些材料属于尼龙-3 家族，是通过 β-内酰胺的开环聚合反应制备的。最好的尼龙-3 聚合物在混合脂膜中显示出良好的体外表面活性。脉动气泡表面活性测定法的数据表明，含有表面活性最强的聚合物的薄膜所具有的吸附性和动态循环特性超过了用于模拟 SP-B 的离散肽。在尼龙-3 共聚物上连接一个 N 端十八碳酰单位可降低表面积压缩百分比，从而达到较低的最小表面张力，从而进一步提高了性能。
• Methylene carbamate linkers for use with targeted-drug conjugates
  申请人：Seagen Inc.

  公开号：US11116847B2

  公开（公告）日：2021-09-14

  The present invention provides Ligand-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.

  本发明提供了包含亚甲基氨基甲酸酯单元的配体-药物共轭物和药物-连接体化合物。本发明特别提供了配体-药物共轭物，其中配体-药物共轭物由具有亚甲基氨基甲酸酯单元的自巯基组装单元组成，用于将药物与靶向配体共轭；本发明还提供了配体-药物共轭物的制备和使用方法及其中间体。本发明的配体-药物共轭物在循环中是稳定的，但一旦从肿瘤细胞附近或内部的共轭物中释放出游离药物，就能造成细胞死亡。
• EARLE, MARTYN J.;FAIRHURST, ROBIN A.;HEANEY, HARRY;PAPAGEORGIOU, GEORGE;W+, TETRAHEDRON LETT., 31,(1990) N9, C. 4229-4232
  作者：EARLE, MARTYN J.、FAIRHURST, ROBIN A.、HEANEY, HARRY、PAPAGEORGIOU, GEORGE、W+

  DOI：——

  日期：——